December 17, 2015 / 6:55 AM / 4 years ago

Belgium's Galapagos signs $2 billion deal with U.S. group Gilead

BRUSSELS (Reuters) - Belgian biotech company Galapagos (GLPG.AS) has signed a development deal for drugs targeting inflammatory diseases potentially worth more than $2 billion with U.S. group Gilead (GILD.O).

For the deal, which concerns experimental drug filgotinib, Galapagos will receive a $725 million upfront payment and may receive up $1.35 billion in payments if certain targets are met as well as royalties once the drug enters the market.

The $725 million upfront payment is made up of a $300 million license payment and a $425 million equity investment, Galapagos said.

The capital investment will be made through the acquisition of Galapagos shares at 58 euros each, a 20 percent premium to the average closing price over the past 30 days, the group added. After the transaction, Gilead will own a 15 percent stake.

Filgotinib may start final clinical trials (Phase III) for rheumatoid arthritis and Crohn’s disease in 2016, Galapagos said.

Reporting by Robert-Jan Bartunek; Editing by Biju Dwarakanath

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below